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Can We Prevent Heart Failure
With Exercise?*
Christopher M. O’Connor, MD,
Tariq Ahmad, MD, MPH
Durham, North Carolina
“May I suggest that more attention be paid to the simple rules
of health . . . . These, if adequately carried out, especially by
candidates for certain diseases such as hypertension and coronary
atherosclerosis, might . . . prevent or delay the onset of these
diseases.”
—Dr. Paul Dudley White (1)
Although important gains have been made in the treatment
of heart failure with pharmacological and device therapies,
there is a need for new approaches that are safe and effective,
particularly in the elderly. Targeting patients with stage A
heart failure, those at high risk of developing clinical heart
failure but without detectable structural heart disease, is a
worthwhile strategy (2). Lifestyle interventions, such as
exercise, are especially appealing because they can be per-
sonalized, are cost-effective, and carry an intuitive appeal.
See page 2539
In this issue of the Journal, deFilippi et al. (3) report an
nalysis of 2,933 participants in the CHS (Cardiovascular
ealth Study) composed of older adults (65 years of age and
lder) who were free of heart failure at study onset.
-terminal pro–B-type natriuretic peptide (NT-proBNP)
nd cardiac troponin T levels were measured at baseline and
to 3 years later. Available data on self-reported physical
ctivity and walking pace were developed into a previously
alidated composite activity score. The investigators found
hat the probability of significant increases in both bio-
arker concentrations between baseline and follow-up visits
as inversely related to physical activity scores. Compared
ith participants with the lowest score (worst), those with
he highest activity scores (best) had half the risk of an
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to the contents of this paper to disclose.increase in NT-proBNP (odds ratio: 0.50; 95% confidence
interval: 0.33 to 0.77) and a third of the risk of an increase
in cardiac troponin T (odds ratio: 0.30; 95% confidence
interval: 0.16 to 0.55). Within 3 clinically relevant catego-
ries of activity (low, moderate, or high), increases in either
biomarker identified those at increased risk of new-onset
heart failure.
This study simultaneously addresses key questions about
the role of exercise in heart failure among the elderly, both
at the population and molecular levels. The incidence and
prevalence of heart failure are growing dramatically in this
age group, but current therapeutic agents have failed to yield
substantial improvements in clinically relevant outcomes
(4). Data from nonrandomized and 14 small phase II
randomized, controlled trials, as well as the landmark
HF-ACTION (Heart Failure: A Controlled Trial Investi-
gating Outcomes of Exercise Training) study of 2,300
heart failure patients, have supported the conclusion that
exercise training improves quality of life and exercise capac-
ity, and reduces the risk of heart failure hospitalization
(5–7). Professional societies advocate regular physical activ-
ity and exercise training in patients with heart failure, and
recently published European guidelines have afforded these
recommendations 1A status (8–10). Nonetheless, this treat-
ment modality remains significantly underused in real-
world settings, and its effectiveness in elderly patients with
early stage heart failure has not been well studied (11). The
current study adds credence to the notion that this popula-
tion, too, may benefit from exercise.
Previous studies of the mechanisms by which exercise
promotes cardiovascular health have focused largely on
physiological parameters (12). As our understanding of
heart failure pathophysiology has shifted from adverse
hemodynamics to maladaptive molecular mechanisms, there
is greater interest in examining the effects of therapeutics on
biological processes via assessment of biomarkers (13).
atriuretic peptides provide key information about disease
tability that can potentially be used to guide therapeutic
ecisions (14). The ability of commonly used biomarkers to
hange with exercise intensity and their relationship to heart
ailure events is an important finding. This observation, if
onfirmed in future studies, may put forth surrogate end-
oints that explore the relationship between exercise train-
ng and cardiovascular health in understudied patient pop-
lations. These findings also provide an impetus for future
nvestigations into how physical activity modifies a variety of
iological processes, such as inflammation and ventricular
emodeling, via serial measurements of representative bio-
arkers. Finally, the possibility that biomarker measure-
ent might provide an objective assessment of exercise
fficacy, for which clinicians currently have no reliable
easure, is an exciting proposition and deserves further
valuation with a controlled trial.
The authors are to be commended for their investigationf a clinically important question that has rarely been
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be acknowledged. This study was not a randomized com-
parison of exercise training versus usual care, and the results
cannot be used to establish causality. The propensity to
exercise at high levels is often associated with less sick
patients who may be able to demonstrate greater changes in
biomarkers as well as fewer heart failure events. Addition-
ally, measurements of exercise activity were qualitative and
self-reported. These observations, therefore, require valida-
tion in an independent dataset that has appropriate controls
and uses quantitative measures of exercise performance and
cardiovascular fitness, such as peak VO2 and 6-min walk
istance. Despite these limitations, such studies catalyze
urther investigations that will help advance the field and
ositively contribute to our knowledge of exercise as a
reventive and therapeutic intervention.
At present, the totality of evidence from observational
tudies and randomized, controlled trials suggests that
xercise is good for the heart, even in the elderly. Biomarker
nalyses are uncovering new mechanisms by which exercise
an slow the progression of cardiovascular disease and
ossibly prevent progression to heart failure. However, key
uestions remain: How do the benefits of exercise vary
ccording to the stage of heart failure? How do frequency,
ntensity, and duration of exercise training influence out-
omes? What is the minimum adherence rate necessary to
chieve benefit? What is the mechanism of benefit? Can
iomarkers be used as reliable surrogate markers of exercise
fficacy or as measures of adherence? Despite many gains
nd the multitude of questions that remain, we echo Dr.
hite’s firm belief in the vital importance of regular
xercise for a healthy life.
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